The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
|Articles|June 2, 2001
- Pharmaceutical Technology-06-02-2001
- Volume 25
- Issue 6
Measurement of Intrinsic Drug Dissolution Rates Using Two Types of Apparatus
The evaluation of the intrinsic dissolution rate of an active pharmaceutical ingredient can be used to demonstrate chemical purity and equivalency. The authors used a rotating disk system and a stationary disk system to determine the intrinsic dissolution rates of various model drugs.
Advertisement
Articles in this issue
over 25 years ago
Viral Clearance Strategies for Biopharmaceutical Safetyover 25 years ago
Outsourcing Outlookover 25 years ago
Managing Risks and Resourcesover 25 years ago
Blister News: COC Resin, Foil, and Lidding Innovationsover 25 years ago
Managing the Risks in Outsourcingover 25 years ago
Systemic Drug Delivery via the Buccal Mucosal RouteAdvertisement
Related to this article
The Leadership Summit will bring senior pharma executives together to discuss supply chain resilience, medicine security, and manufacturing capacity amid growing geopolitical fragmentation.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement